Although the incidence of ovarian cancer is low, mortality from this cancer is high due to discovery at a late stage in the majority of cases. So it seems worthwhile to detect ovarian cancer at an early stage. The clinical presentation is nonspecific, thus screening tools have been evaluated. The most efficient screening technique includes two steps: evaluation of CA-125 and then sonography in case of abnormal results of CA-125. Two main studies have been performed in large populations. The PLCO-study has led to negative results: no reduction in ovarian cancer mortality in the screening group with an important increase in surgical morbidity. The final results of the UKCTOCS-study will be known in two years. Currently these data can't allow ...
Ovarian cancer screening using pelvic examination, CA-125 serum tumor marker, transvaginal ultrasoun...
Ovarian cancer is the second most lethal gynecological malignancy. The tumour biomarker CA125 has be...
OBJECTIVE: To estimate the effectiveness of ovarian cancer screening with CA 125 and transvaginal so...
Ovarian cancer accounts for a minority of female cancers but remains the leading cause of death from...
Ovarian cancer is predominantly a disease of postmenopausal women which presents at a late stage and...
The review is devoted to the problem of active detection and diagnosis of early stages of ovarian ca...
Purpose To assess the effectiveness of annual ovarian cancer screening (transvaginal ultrasound and ...
This paper investigates the potential role CA-125 has in screening for ovarian cancer. Specifically,...
Despite advances in therapy, ovarian cancer remains the most deadly of the gynecological cancers. Le...
Presented here are scientific reports which add considerable information to the area of early stage ...
Ovarian cancer is the foremost cause of gynecological cancer death in the developed world, as it is ...
Ovarian cancer is associated with an overall mortality of 75%, but can be cured in up to 90 % of cas...
Ovarian cancer is characterize by few early symptoms, presentation at an advanced stage, and poor su...
Abstract. Despite advances in therapy, ovarian cancer remains the most deadly of the gynecological c...
Women with a family history of ovarian cancer represent a high-risk group for the development of epi...
Ovarian cancer screening using pelvic examination, CA-125 serum tumor marker, transvaginal ultrasoun...
Ovarian cancer is the second most lethal gynecological malignancy. The tumour biomarker CA125 has be...
OBJECTIVE: To estimate the effectiveness of ovarian cancer screening with CA 125 and transvaginal so...
Ovarian cancer accounts for a minority of female cancers but remains the leading cause of death from...
Ovarian cancer is predominantly a disease of postmenopausal women which presents at a late stage and...
The review is devoted to the problem of active detection and diagnosis of early stages of ovarian ca...
Purpose To assess the effectiveness of annual ovarian cancer screening (transvaginal ultrasound and ...
This paper investigates the potential role CA-125 has in screening for ovarian cancer. Specifically,...
Despite advances in therapy, ovarian cancer remains the most deadly of the gynecological cancers. Le...
Presented here are scientific reports which add considerable information to the area of early stage ...
Ovarian cancer is the foremost cause of gynecological cancer death in the developed world, as it is ...
Ovarian cancer is associated with an overall mortality of 75%, but can be cured in up to 90 % of cas...
Ovarian cancer is characterize by few early symptoms, presentation at an advanced stage, and poor su...
Abstract. Despite advances in therapy, ovarian cancer remains the most deadly of the gynecological c...
Women with a family history of ovarian cancer represent a high-risk group for the development of epi...
Ovarian cancer screening using pelvic examination, CA-125 serum tumor marker, transvaginal ultrasoun...
Ovarian cancer is the second most lethal gynecological malignancy. The tumour biomarker CA125 has be...
OBJECTIVE: To estimate the effectiveness of ovarian cancer screening with CA 125 and transvaginal so...